Latest news

• Novartis' Zortress cleared by FDA for liver transplants

  After the 30-day period, they were randomised to receive Zortress plus reduced-exposure tacrolimus, Zortress followed by tacrolimus withdrawal at four months, or standard-exposure tacrolimus only. ... Zortress/Certican achieved sales of $210m in

• FDA approves Afinitor for pancreatic cancer

  In the US, everolimus is also available in different dosage strengths under the trade name Zortress for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving

• FDA clears test for Novartis' Zortress

  The US Food and Drug Administration has cleared a test that monitors blood levels of Novartis' recently approved immunosuppressant Zortress. ... The US Food and Drug Administration (FDA) has cleared a test that monitors blood levels of Novartis'

• Getting the GIST

  Several mTOR antagonists have already been launched for different cancers and could therefore be prescribed as off-label therapy; these include everolimus (Zortress/Certican, Novartis), sirolimus (Rapamune, Wyeth) and temsirolimus (Torisel,

• Novartis' net income up 15 per cent for Q2

  Successful launches included Exjade (deferasirox), which made $192m after receiving regulatory approvals in the US and Europe for the treatment of chronic iron overload, and Certican/Zortress (everolimus) which made $26m